Publication: Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results
2
Issued Date
2019-01-01
Resource Type
ISSN
15280020
00064971
00064971
Other identifier(s)
2-s2.0-85074346534
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Blood. Vol.134, No.22 (2019), 1973-1982
Suggested Citation
Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Pratima Chowdary, Hermann Eichler, Victor Jiménez-Yuste, Kaan Kavakli, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupancic-Salek, Johannes Oldenburg Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results. Blood. Vol.134, No.22 (2019), 1973-1982. doi:10.1182/blood.2019001542 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/50412
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results
Other Contributor(s)
Vanderbilt University Medical Center
Universitäts-Klinikum Bonn und Medizinische Fakultät
Belfast Health and Social Care Trust
Aarhus Universitet
NHS Foundation Trust
Hospital Universitario La Paz
Nagoya University Hospital
Universitätsklinikum des Saarlandes Medizinische Fakultät der Universität des Saarlandes
Ege Üniversitesi
Azienda Ospedaliera Careggi
Josip Juraj Strossmayer University of Osijek
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Keck School of Medicine of USC
Skånes universitetssjukhus
University of Zagreb School of Medicine
Indiana Hemophilia and Thrombosis Center
Universitäts-Klinikum Bonn und Medizinische Fakultät
Belfast Health and Social Care Trust
Aarhus Universitet
NHS Foundation Trust
Hospital Universitario La Paz
Nagoya University Hospital
Universitätsklinikum des Saarlandes Medizinische Fakultät der Universität des Saarlandes
Ege Üniversitesi
Azienda Ospedaliera Careggi
Josip Juraj Strossmayer University of Osijek
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Keck School of Medicine of USC
Skånes universitetssjukhus
University of Zagreb School of Medicine
Indiana Hemophilia and Thrombosis Center
Abstract
© 2019 by The American Society of Hematology. Results from the main parts (24 weeks) of 2 concizumab phase 2 trials are presented: explorer4 in hemophilia A (HA) or B (HB) with inhibitors (HAwI/HBwI) and explorer5 in HA. The trials aimed to evaluate the efficacy of daily subcutaneous concizumab prophylaxis (evaluated as annualized bleeding rate [ABR] at last dose level), with secondary objectives being safety and immunogenicity (assessed as number of adverse events [AEs] and antidrug antibodies [ADAs]). Patients received 0.15 mg/kg concizumab, with potential dose escalation to 0.20 and 0.25 mg/kg (if ‡3 spontaneous bleeding episodes within 12 weeks of concizumab treatment). Relevant pharmacokinetic/pharmacodynamic (PK/PD) parameters were assessed. Thirty-six HA, 9 HAwI, and 8 HBwI patients were exposed to concizumab. Most inhibitor patients (15 of 17; 88.2%) did not escalate the dose; all patients chose to continue to the extension phase of the trials. Clinical proof of concept for prevention of bleeding episodes was demonstrated in both trials. Estimated ABRs in HAwI and HBwI were lower vs HA: 3.0 (95% confidence interval [CI], 1.7; 5.3) and 5.9 (95% CI, 4.2; 8.5) vs 7.0 (95% CI, 4.6; 10.7), respectively. PK/PD results were as expected, with no difference between hemophilia subtypes for concizumab exposure, free tissue factor pathway inhibitor, thrombin generation, prothrombin fragment 112, and D-dimers. Concizumab was safe and well tolerated (no severe AEs, AE-related withdrawals, or thromboembolic events). Three patients had (very low to medium titer) ADA1 tests in each trial, with no observed clinical effect. These results support further development of concizumab as a daily prophylactic treatment in all hemophilia patients.